Amundi
RXST icon

Amundi’s RxSight RXST Stock Holding History

Amundi’s Portfolio RXST Stock Details RXST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-50
Closed -$811 – 2080
2025
Q1 		$811 Buy
50
+29
+138% +$862 ﹤0.01% 2068
2024
Q4 		$725 Buy
+21
New +$947 ﹤0.01% 2065

Other funds holding RXST

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
NSGL
No Street GP LP San Francisco, California $1.5B AUM 34.53% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Amundi's RXST Position: Q2 2025 in Review

Amundi sold out of RxSight (RXST) in Q2 2025, closing a stake of 50 shares — an estimated $811 sold.

Amundi first reported a position in RXST in Q4 2024 and held it in 2 quarters. The position peaked at $811 in Q1 2025. 174 funds tracked by Wall St. Rank hold RXST as of Q2 2025.

  • Amundi reported no remaining RxSight position as of Q2 2025 after selling out during the quarter.
  • Amundi sold 50 RxSight shares in Q2 2025, an estimated $811.
  • Amundi first reported a position in RxSight in Q4 2024 and held it in 2 quarters.
  • Amundi's RxSight position peaked at $811 in Q1 2025.
  • 174 funds tracked by Wall St. Rank held RxSight as of Q2 2025.

Based on Amundi's 13F filing for Q2 2025, filed 13 Aug 2025.